FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247136531> ?p ?o ?g. }

• W2247136531 endingPage "2091" @default.
• W2247136531 startingPage "2091" @default.
• W2247136531 abstract "Abstract Introduction: Bendamustine is a purine analog/alkylator hybrid agent with a unique mechanism of action, which has shown good clinical efficacy and acceptable tolerability in various hematological malignancies, including Hodgkin’s disease, non-Hodgkin’s lymphoma, and multiple myeloma. Patients and Methods: The efficacy and safety of bendamustine and chlorambucil have been compared in a randomized, open-label, multicenter, Phase III trial in patients with previously untreated advanced (Binet stage B/C) B cell chronic lymphocytic leukemia: an updated analysis from this trial is presented here. Patients were randomized to receive bendamustine (100 mg/m2 on days 1 + 2) or chlorambucil (0.8 mg/kg on days 1 and 15) for up to 6 treatment cycles. The median cumulative dose per patient was 1820 mg and 517 mg for bendamustine and chlorambucil, respectively. The primary endpoints were overall remission rate (ORR), which was defined as complete response, nodular partial response or partial response, and progression-free survival (PFS). Secondary endpoints included overall survival (OS) and safety. The response to treatment was evaluated by a blinded Independent Response Assessment Committee. Results: A total of 319 patients were randomized (162 bendamustine, 157 chlorambucil), of whom all were included in the efficacy analysis and 312 were evaluable for safety. The mean (± SD) number of treatment cycles was 4.8 ± 1.7 in the bendamustine group and 4.6 ± 1.7 in the chlorambucil group; the median duration of follow-up was 29.2 months (29.8 bendamustine, 27.8 chlorambucil). The ORR was significantly higher with bendamustine than with chlorambucil (67% versus 30%, P&lt;0.0001). The median PFS was 21.5 months with bendamustine and 8.3 months with chlorambucil (P&lt;0.0001). No difference in OS was seen between groups. Most doses were given on schedule. The mean overall relative dose intensity was 86% and 96% in the bendamustine and chlorambucil treatment groups, respectively. At least 1 grade 3/4 neutropenia occurred in 43% of bendamustine-treated patients and 21% of those receiving chlorambucil. Grade 3/4 infections were documented in 7% of bendamustine-treated patients and 4% of chlorambucil-treated patients. Conclusion: This study has shown that bendamustine offers significantly greater efficacy than chlorambucil, with manageable toxicity, and should be considered as first-line chemotherapy for patients with advanced B-CLL." @default.
• W2247136531 created "2016-06-24" @default.
• W2247136531 creator A5004066423 @default.
• W2247136531 creator A5006870353 @default.
• W2247136531 creator A5008703895 @default.
• W2247136531 creator A5010593743 @default.
• W2247136531 creator A5010990321 @default.
• W2247136531 creator A5016736531 @default.
• W2247136531 creator A5019048597 @default.
• W2247136531 creator A5021372104 @default.
• W2247136531 creator A5024160619 @default.
• W2247136531 creator A5039819830 @default.
• W2247136531 creator A5047684235 @default.
• W2247136531 creator A5051276031 @default.
• W2247136531 creator A5054363370 @default.
• W2247136531 creator A5071466957 @default.
• W2247136531 creator A5072698345 @default.
• W2247136531 creator A5077837562 @default.
• W2247136531 date "2008-11-16" @default.
• W2247136531 modified "2023-10-15" @default.
• W2247136531 title "Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study." @default.
• W2247136531 doi "https://doi.org/10.1182/blood.v112.11.2091.2091" @default.
• W2247136531 hasPublicationYear "2008" @default.
• W2247136531 type Work @default.
• W2247136531 sameAs 2247136531 @default.
• W2247136531 citedByCount "17" @default.
• W2247136531 countsByYear W22471365312012 @default.
• W2247136531 countsByYear W22471365312019 @default.
• W2247136531 crossrefType "journal-article" @default.
• W2247136531 hasAuthorship W2247136531A5004066423 @default.
• W2247136531 hasAuthorship W2247136531A5006870353 @default.
• W2247136531 hasAuthorship W2247136531A5008703895 @default.
• W2247136531 hasAuthorship W2247136531A5010593743 @default.
• W2247136531 hasAuthorship W2247136531A5010990321 @default.
• W2247136531 hasAuthorship W2247136531A5016736531 @default.
• W2247136531 hasAuthorship W2247136531A5019048597 @default.
• W2247136531 hasAuthorship W2247136531A5021372104 @default.
• W2247136531 hasAuthorship W2247136531A5024160619 @default.
• W2247136531 hasAuthorship W2247136531A5039819830 @default.
• W2247136531 hasAuthorship W2247136531A5047684235 @default.
• W2247136531 hasAuthorship W2247136531A5051276031 @default.
• W2247136531 hasAuthorship W2247136531A5054363370 @default.
• W2247136531 hasAuthorship W2247136531A5071466957 @default.
• W2247136531 hasAuthorship W2247136531A5072698345 @default.
• W2247136531 hasAuthorship W2247136531A5077837562 @default.
• W2247136531 hasConcept C126322002 @default.
• W2247136531 hasConcept C141071460 @default.
• W2247136531 hasConcept C143998085 @default.
• W2247136531 hasConcept C197934379 @default.
• W2247136531 hasConcept C2776694085 @default.
• W2247136531 hasConcept C2776755627 @default.
• W2247136531 hasConcept C2777063308 @default.
• W2247136531 hasConcept C2777866208 @default.
• W2247136531 hasConcept C2777938653 @default.
• W2247136531 hasConcept C2778375690 @default.
• W2247136531 hasConcept C2778461978 @default.
• W2247136531 hasConcept C2781442060 @default.
• W2247136531 hasConcept C71924100 @default.
• W2247136531 hasConcept C90924648 @default.
• W2247136531 hasConceptScore W2247136531C126322002 @default.
• W2247136531 hasConceptScore W2247136531C141071460 @default.
• W2247136531 hasConceptScore W2247136531C143998085 @default.
• W2247136531 hasConceptScore W2247136531C197934379 @default.
• W2247136531 hasConceptScore W2247136531C2776694085 @default.
• W2247136531 hasConceptScore W2247136531C2776755627 @default.
• W2247136531 hasConceptScore W2247136531C2777063308 @default.
• W2247136531 hasConceptScore W2247136531C2777866208 @default.
• W2247136531 hasConceptScore W2247136531C2777938653 @default.
• W2247136531 hasConceptScore W2247136531C2778375690 @default.
• W2247136531 hasConceptScore W2247136531C2778461978 @default.
• W2247136531 hasConceptScore W2247136531C2781442060 @default.
• W2247136531 hasConceptScore W2247136531C71924100 @default.
• W2247136531 hasConceptScore W2247136531C90924648 @default.
• W2247136531 hasIssue "11" @default.
• W2247136531 hasLocation W22471365311 @default.
• W2247136531 hasOpenAccess W2247136531 @default.
• W2247136531 hasPrimaryLocation W22471365311 @default.
• W2247136531 hasRelatedWork W1888279331 @default.
• W2247136531 hasRelatedWork W1998954504 @default.
• W2247136531 hasRelatedWork W2031665320 @default.
• W2247136531 hasRelatedWork W2144395078 @default.
• W2247136531 hasRelatedWork W2163348695 @default.
• W2247136531 hasRelatedWork W2247136531 @default.
• W2247136531 hasRelatedWork W2248735241 @default.
• W2247136531 hasRelatedWork W2347056622 @default.
• W2247136531 hasRelatedWork W4207041128 @default.
• W2247136531 hasRelatedWork W4237277979 @default.
• W2247136531 hasVolume "112" @default.
• W2247136531 isParatext "false" @default.
• W2247136531 isRetracted "false" @default.
• W2247136531 magId "2247136531" @default.
• W2247136531 workType "article" @default.